2022 Fiscal Year Final Research Report
Establishment of a novel drug delivery system for targeting cancer stem cells based on the structual analysis of tumor blood vesseles.
| Project/Area Number |
20K07155
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
檜垣 和孝 岡山大学, 医歯薬学域, 教授 (60284080)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | がん幹細胞 / スフェア培養 / 乳がん |
|---|
| Outline of Final Research Achievements |
We have established subclones from single cell of mouse 4T1 breast cancer cell line by sphere culture in stem cell medium. Then, we found that established subclones showed cancer stem-like properteis such as high expression of CD44 variant, a cancer stem cell marker, in vivo high tumorigenicity, high expression of stem cell-related genes, and resistance to doxorubicin. Furtheremore, we suggested that MRP1 would contribute to the doxrubicin resistance. These results indicated that established cancer stem cell clones would useful for investigating the cancer stem cell-targeting therapy.
|
| Free Research Field |
薬剤学
|
| Academic Significance and Societal Importance of the Research Achievements |
がん幹細胞は、がんの再発や転移に重要であることが知られているものの、ヒトの腫瘍組織から作成することが多く、市販されているものがほとんど無いため、実験材料を得ることすら難しい。本研究において、マウス乳がん由来4T1細胞からがん幹細胞様の特性をもつモデル細胞株を樹立することに成功したため、今後は、薬物送達に利用できる新規細胞表面抗原の探索研究、がん幹細胞に有効な薬剤のスクリーニング研究など、がん幹細胞を標的とした新規治療法の開発に役立つと考えられる。
|
